文献速递间质性肺疾病

霉酚酸酯或硫唑嘌呤治疗慢性过敏性肺炎的肺功能影响

Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.
PubMed 文献 · Chest · 2016-11-03

结论认为霉酚酸酯或硫唑嘌呤与DLCO改善相关,需前瞻性随机试验验证。

核心结论

  • 霉酚酸酯或硫唑嘌呤治疗与慢性过敏性肺炎患者DLCO改善相关。
  • 需前瞻性随机试验验证其有效性。

研究设计与样本

  • 回顾性研究,从四个间质性肺病中心识别接受霉酚酸酯或硫唑嘌呤治疗的慢性过敏性肺炎患者。
  • 中位随访时间为治疗开始后11个月。
  • 采用线性混合效应模型分析治疗前后肺功能变化,校正年龄、性别、吸烟史和泼尼松使用。

临床怎么用

  • 对于慢性过敏性肺炎患者,霉酚酸酯或硫唑嘌呤可作为改善DLCO的治疗选择。
  • 治疗决策需结合患者具体情况,并注意FVC可能无显著改善。

局限性

  • 回顾性研究设计。
  • 缺乏随机对照,可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment of chronic hypersensitivity pneumonitis (cHP) often includes systemic oral corticosteroids, but the optimal pharmacologic management remains unclear. The morbidity associated with prednisone has motivated the search for alternative therapies. We aimed to determine the effect of treatment with mycophenolate mofetil (MMF) or azathioprine (AZA) on lung function in patients with cHP. METHODS: Patients with cHP treated with either MMF or AZA were retrospectively identified from four interstitial lung disease centers. Change in lung function before and after treatment initiation was analyzed using linear mixed-effects modeling (LMM), adjusting for age, sex, smoking history, and prednisone use. RESULTS: Seventy patients were included: 51 were treated with MMF and 19 with AZA. Median follow-up after treatment initiation was 11 months. Prior to treatment initiation, FVC and diffusion capacity of the lung for carbon monoxide (Dlco) % predicted were declining at a mean rate of 0.12% (P < .001) and 0.10% (P < .001) per month, respectively. Treatment with either MMF or AZA was not associated with improved FVC (0.5% at 1 year; P = .46) but was associated with a statistically significant improvement in Dlco of 4.2% (P < .001) after 1 year of treatment. Results were similar in the subgroup of patients treated with MMF for 1 year; the FVC increased nonsignificantly by 1.3% (P = .103) and Dlco increased by 3.9% (P < .001). CONCLUSIONS: Treatment with MMF or AZA is associated with improvements in Dlco in patients with cHP. Prospective randomized trials are needed to validate their effectiveness for cHP.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Morisset J, Johannson KA, Vittinghoff E, et al. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest. 2016. PMID: 27816444. doi:10.1016/j.chest.2016.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。